SML3785
Levonadifloxacin
≥98% (HPLC)
别名:
(5S)-9-Fluoro-6,7-dihydro-8-(4-hydroxy-1-piperidinyl)-5-methyl-1-oxo-1H,5H-benzo[ij]quinolizine-2-carboxylic acid, (S)-(-)-Nadifloxacin, (S)-9-Fluoro-8-(4-hydroxypiperidin-1-yl)-5-methyl-1-oxo-6,7-dihydro-1H,5H-pyrido[3,2,1-ij]quinoline-2-carboxylic acid, WCK 771
登录查看公司和协议定价
所有图片(2)
About This Item
经验公式（希尔记法）:
C19H21FN2O4
CAS号:
分子量:
360.38
MDL编号:
UNSPSC代码:
51111800
UNSPSC代码:
12352200
NACRES:
NA.21
推荐产品
1 of 4
此商品 | F7177 | F7427 | F7802 |
|---|---|---|---|
| capacity 70 mL | capacity - | capacity - | capacity - |
| sterility sterile | sterility sterile; γ-irradiated | sterility sterile; γ-irradiated | sterility sterile; γ-irradiated |
| packaging case of 30 ea | packaging case of 200 (20 packs x 10 flasks) | packaging case of 100 ea (20 packs x 5 flasks) | packaging case of 30 ea (6 packs x 5 flasks) |
| manufacturer/tradename Nunc 159934 | manufacturer/tradename Nunc 156340 | manufacturer/tradename Nunc 156472 | manufacturer/tradename Nunc 159920 |
生化/生理作用
Levonadifloxacin is a potent benzoquinolizine fluoroquinolone antibiotic that is affective against Gram-positive and Gram-negative bacteria, including methicillin- and quinolone-resistant Staphylococcus aureus, Streptococcus pneumoniae, Streptococcus pyogenes, Haemophilus influenzae, and Moraxella catarrhalis and atypical pathogens. It appears that Levonadifloxacin targets staphylococcal DNA gyrase, unlike other quinolones, which primarily inhibit DNA topoisomerase IV.
Potent benzoquinolizine fluoroquinolone antibiotic that is affective against Gram-positive and Gram-negative bacteria
储存分类代码
11 - Combustible Solids
WGK
WGK 3
闪点(°F)
Not applicable
闪点(°C)
Not applicable
法规信息
新产品
历史批次信息供参考:
分析证书(COA)
Lot/Batch Number
In vitro bactericidal activity of levonadifloxacin (WCK 771) against methicillin- and quinolone-resistant Staphylococcus aureus biofilms
Journal of Medical Microbiology, 68(8), 1129-1136 (2019)
Structural Characterization of the Millennial Antibacterial (Fluoro)Quinolones-Shaping the Fifth Generation
Pharmaceutics, 13(8), 1289-1289 (2021)
Levonadifloxacin, a Novel Broad-Spectrum Anti-MRSA Benzoquinolizine Quinolone Agent: Review of Current Evidence
Drug design, development and therapy, 13, 4351-4365 (2019)
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门
